invest in cc&c

A word of the CEO

A treatment available in 4 years

Financing Requirements

We need 250 K € to build the prototype and test it on human pancreatic cancer grafted in the mouse pancreas: this will be the “Proof of Efficiency”. Then we will look for an investor and then an industrial partner to move to the patient scale. The construction of a prototype for the man will cost 250 K €. We believe that the decisive step is the Proof of In Vivo Effectiveness, which marks the end of the research, followed by the publication of an article in a major scientific journal and conference presentations.

The development is estimated at 5 M € (3 M € for the pre-clinic and 2 M € for the clinic) and will go through an agreement with an industrialist.

Learn more about our innovation…

All the capital raised will be used for Research & Development:

• Progressive recruitment of employees including researchers and a product manager;
• Feasibility studies in electrotechnology and nanoparticles, studies of evidence of in vivo efficacy in rodents; construction of a demonstrator and then a prototype;
• Concurrent patenting, accompanying development.

Why is the development so quick?

The consideration of mechanical signals in the formation and development of cancer is currently on the rise: the creation of an Institute of Mechanobiology in Singapore, many publications from California and New England. The two partnerships we have formed, one with Stanford University, the other within a European consortium with the Faculty of Medicine of Bichat, demonstrate that the scientific community is seizing the opportunities opened by Physical Oncology.

Health products are often developed over 10 years. Because we are working under the rules of physics and not biology, because the toxicity of our two devices is known, because up to a certain point, we can model from the previous results, and therefore predict the following experiment, we are convinced that our development can be remarkably fast.

Which investment strategy ?

The life of our company has so far been conducted on regular fundraising from investors wishing to optimize their ISF (french wealth tax). The transformation of this tax in 2017, and the progress of our work, require us to change our funding model.

A number of public grants have become available to us since we formed a consortium in Europe and a consortium in the United States. If we get them, these funds will allow us to focus on our research work for a few years. But to be eligible for these calls for projects, we must strengthen our capital position, this is one of the reasons for the 2018 fundraising. Moreover, if we do not get these funds, we will have to finance the experiments by ourselves.

We are now looking for Business Angels investors or companies in the healthcare sector, able to federate institutional investors around us and carry out the clinical and pre-clinical development of our innovation.

For small investors, this is probably the last opportunity to enter our capital and hope for a significant profit in a few years.

MARKET DATA AND REVENUE ESTIMATES

Treatment will be administered on prescription, reimbursed by health insurance systems.

One can outline a simulation (all figures excluding taxes) :
• A machine, around 2M €.
• A reimbursement of the act of passing under machine, around 1 000 €.
• An interesting price for the consumable (nanoparticles) with high margins : 3 000 €.
For France alone with 3,000 pancreas inoperable 12 M € / year.
In the USA, 16 000 patients, or 77 M $ / year.

Beyond pancreatic cancer, other applications are possible in the direction of glioblastoma, primary liver cancer, etc.

For more information, see our Executive Summary.

Our needs

on road to the Proof of efficacy

2018 fundraising : breakdown of expenditure

A bet that is both reasonnable and generous

On the side of reason, there is a true breaking innovation protected by patent, the opening of a market without competition, a pragmatic development plan with the desired association with an industrialist.
On the side of generosity, there are patients who will find a therapeutic solution to a disease in full expansion, and participation in the emergence of a new way of understanding and caring for cancer.

Financial documents

We make available to potential investors the following documents :

Executive Summary

Balance Sheet and Income Statement 2017

Call for subscription document…

Don’t hesitate to contact us for more details.

Financial news

Results for the 3rd quarter 2018

- RESULTS OF THE CALL FOR EUROPEAN PROJECTS FET-OPEN - A NEW RESEARCH PROJECT WITH THE UNIVERSITY OF MONTPELLIERWe have received the answer from the European Commission: unfortunately, it is negative. However, we get a very good grade, and the comments of the...

read more

Results for the second quarter 2018

- EUROPEAN GRANT APPLICATION FET OPEN: 1.8 MILLION EURO REQUESTED, RESPONSE ON OCTOBER 16TH, 2018 - AFTER STANFORD UNIVERSITY, NEW PARTNERSHIPS IN PERSPECTIVE On May 16th, we submitted an application for a grant of 1.8 million Euro from the European Commission as part...

read more

NanoStress: we answered the FET-Open call for projects

The FET-Open call of the European Commission finances disruptive innovation research projects capable of « changing the world ». We did not need it any less, so we submitted today a nomination file within the NanoStress consortium, in order to obtain the Proof of...

read more

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles

invest in cc&c

A word of the CEO

A treatment available in 4 years

Financing Requirements

We need 250 K € to build the prototype and test it on human pancreatic cancer grafted in the mouse pancreas: this will be the “Proof of Efficiency”. Then we will look for an investor and then an industrial partner to move to the patient scale. The construction of a prototype for the man will cost 250 K €. We believe that the decisive step is the Proof of In Vivo Effectiveness, which marks the end of the research, followed by the publication of an article in a major scientific journal and conference presentations.

The development is estimated at 5 M € (3 M € for the pre-clinic and 2 M € for the clinic) and will go through an agreement with an industrialist.

Learn more about our innovation…

All the capital raised will be used for Research & Development:

• Progressive recruitment of employees including researchers and a product manager;
• Feasibility studies in electrotechnology and nanoparticles, studies of evidence of in vivo efficacy in rodents; The construction of a demonstrator and then a prototype;
• Concurrent patenting, accompanying development.

Why is the development so quick ?

Why a development so fast?

Our technology is based on the laws of physics. One can then develop partially in parallel; We can thus model; The biological hazard is very small compared to a molecule or a biological signal. Finally, human uses of the two components showed their very low toxicity.

Which investment strategy ?

The life of our company has so far been conducted on regular fundraising from investors wishing to optimize their ISF (french wealth tax). The transformation of this tax in 2017, and the progress of our work, require us to change our funding model.

A number of public grants have become available to us since we formed a consortium in Europe and a consortium in the United States. If we get them, these funds will allow us to focus on our research work for a few years. But to be eligible for these calls for projects, we must strengthen our capital position, this is one of the reasons for the 2018 fundraising. Moreover, if we do not get these funds, we will have to finance the experiments by ourselves.

We are now looking for Business Angels investors or companies in the healthcare sector, able to federate institutional investors around us and carry out the clinical and pre-clinical development of our innovation.

For small investors, this is probably the last opportunity to enter our capital and hope for a significant profit in a few years.

WHY INVEST IN cc&c ?

Treatment will be administered on prescription, reimbursed by health insurance systems.

One can outline a simulation (all figures excluding taxes) :
• A machine, around 2M €.
• A reimbursement of the act of passing under machine, around 1 000 €.
• An interesting price for the consumable (nanoparticles) with high margins : 3 000 €.
For France alone with 3,000 pancreas inoperable 12 M € / year.
In the USA, 16 000 patients, or 77 M $ / year.

Beyond pancreatic cancer, other applications are possible in the direction of glioblastoma, primary liver cancer, etc.

For more information, see our Executive Summary.

 

Our Needs

on the road to Proof of efficacy

2018 fundraising : breakdown of expenditure

A bet that is both reasonable and generous

On the side of reason, there is a true breaking innovation protected by patent, the opening of a market without competition, a pragmatic development plan with the desired association with an industrialist.
On the side of generosity, there are patients who will find a therapeutic solution to a disease in full expansion, and participation in the emergence of a new way of understanding and caring for cancer.

 

 

Financial Documents

We make available to potential investors the following documents :

Executive Summary

Balance Sheet and Income Statement 2017

Call for subscription document…

Don’t hesitate to contact us for more details.

 

 

Financial news

Results for the 3rd quarter 2018

- RESULTS OF THE CALL FOR EUROPEAN PROJECTS FET-OPEN - A NEW RESEARCH PROJECT WITH THE UNIVERSITY OF MONTPELLIERWe have received the answer from the European Commission: unfortunately, it is negative. However, we get a very good grade, and the comments of the...

read more

Results for the second quarter 2018

- EUROPEAN GRANT APPLICATION FET OPEN: 1.8 MILLION EURO REQUESTED, RESPONSE ON OCTOBER 16TH, 2018 - AFTER STANFORD UNIVERSITY, NEW PARTNERSHIPS IN PERSPECTIVE On May 16th, we submitted an application for a grant of 1.8 million Euro from the European Commission as part...

read more

NanoStress: we answered the FET-Open call for projects

The FET-Open call of the European Commission finances disruptive innovation research projects capable of « changing the world ». We did not need it any less, so we submitted today a nomination file within the NanoStress consortium, in order to obtain the Proof of...

read more

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles